# Teva Pharmaceutical (TEVA) — Analyst Forecast

TEVA · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/teva/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 13 | 0 | 0 | 13 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $44.00 | $48.43 | $55.00 | 7 |

Last price $41.11 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 15, 2026 | Barclays | Maintained | Overweight | $47.00 |
| Oct 12, 2026 | JP Morgan | Maintained | Overweight | $50.00 |
| Oct 1, 2026 | TD Cowen | Initiated Coverage | Buy | $55.00 |
| Sep 23, 2026 | Oppenheimer | Initiated Coverage | Outperform | $50.00 |
| Sep 9, 2026 | Leerink Partners | Initiated Coverage | Outperform | $45.00 |
| Sep 4, 2026 | UBS | Maintained | Buy | $48.00 |
| Aug 12, 2026 | Barclays | Maintained | Overweight | $42.00 |
| Jul 28, 2026 | Piper Sandler | Maintained | Overweight | $44.00 |
| May 6, 2026 | Barclays | Maintained | Overweight | $40.00 |
| Apr 30, 2026 | Truist Securities | Maintained | Buy | $45.00 |
| Apr 30, 2026 | Piper Sandler | Maintained | Overweight | $42.00 |
| Apr 30, 2026 | UBS | Maintained | Buy | $42.00 |
| Apr 30, 2026 | JP Morgan | Maintained | Overweight | $40.00 |
| Apr 9, 2026 | B of A Securities | Maintained | Buy | $42.00 |
| Mar 4, 2026 | Piper Sandler | Maintained | Overweight | $41.00 |
| Feb 18, 2026 | Truist Securities | Maintained | Buy | $42.00 |
| Feb 9, 2026 | Goldman Sachs | Maintained | Buy | $45.00 |
| Jan 30, 2026 | Barclays | Maintained | Overweight | $38.00 |
| Jan 29, 2026 | Truist Securities | Maintained | Buy | $38.00 |
| Jan 29, 2026 | Scotiabank | Maintained | Sector Outperform | $40.00 |

## Frequently Asked Questions

### What is the price target for TEVA stock?

The average 12-month analyst price target for Teva Pharmaceutical (TEVA) is $48.43, with a high estimate of $55.00 and a low of $44.00, across 7 analysts.

### Is TEVA a buy, sell, or hold?

Analysts covering Teva Pharmaceutical currently average a Buy rating: 13 buy, 0 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for TEVA?

The average price target of $48.43 implies 17.80% upside from the last price of $41.11.

### What is the latest analyst rating on TEVA?

On Oct 15, 2026, Barclays maintained Teva Pharmaceutical at Overweight with a price target of $47.00.

## Similar Stocks

- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).